Phase 2 Plasma Clinical Trials

46 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 120 of 46 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled580 locationsNCT03866382
Recruiting
Phase 2

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled9 locationsNCT07231952
Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled133 locationsNCT04840602
Recruiting
Phase 1Phase 2

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory
Sanofi258 enrolled26 locationsNCT04643002
Recruiting
Phase 1Phase 2

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Hodgkin LymphomaMultiple MyelomaAcute Myeloid Leukemia (AML)+7 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT05092451
Recruiting
Phase 2

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Multiple MyelomaPlasma Cell Leukemia
University of Utah120 enrolled1 locationNCT05405387
Recruiting
Phase 2

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS28 enrolled18 locationsNCT04915248
Recruiting
Phase 2

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma
Emory University68 enrolled1 locationNCT04776395
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 2

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled17 locationsNCT07387471
Recruiting
Phase 2

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center29 enrolled8 locationsNCT04508790
Recruiting
Phase 2

Personalized NK Cell Therapy in CBT

Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute LeukemiaMyeloproliferative Neoplasm+14 more
Fred Hutchinson Cancer Center68 enrolled10 locationsNCT03779854
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company180 enrolled2 locationsNCT07249905
Recruiting
Phase 2

"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"

Mycoplasma GenitaliumNon-gonococcal Urethritis (NGU)
University of Washington40 enrolled1 locationNCT07088419
Recruiting
Phase 1Phase 2

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple MyelomaPlasmacytoma
Shenzhen Geno-Immune Medical Institute20 enrolled2 locationsNCT06429150
Recruiting
Phase 2

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Multiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT05336383
Recruiting
Phase 2

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center40 enrolled1 locationNCT04216524
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia (PCL)
The First Hospital of Jilin University25 enrolled1 locationNCT07509086